♥
ISIN : INE234A01025
NSE : NOVARTIND
BSE : 500672
Face Value : 5
Industry : Trading
EPS : 34.50
EPS (TTM) : 35.40
Price to Earning (P/E) : 29.79
Book Value : 301.79
Price to Bookvalue (P/B) : 3.41
Dividend Yield : 2 %
Return on Equity (ROE) : 11.21 %
Return on Capital Employed (ROCE) : 16.35 %
Novartis India Limited
ISIN : INE234A01025
NSE : NOVARTIND
BSE : 500672
Face Value : 5
Industry : Trading
EPS : 34.50
EPS (TTM) : 35.40
Price to Earning (P/E) : 29.79
Book Value : 301.79
Price to Bookvalue (P/B) : 3.41
Dividend Yield : 2 %
Return on Equity (ROE) : 11.21 %
Return on Capital Employed (ROCE) : 16.35 %
Novartis India share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 1014 - 1027.75 1.4 % |
| Low / High | 994 - 1028.95 3.5 % |
| Trade Volume | 34,894 |
| 52 Week Low / High | 750 - 1099.9 46.7 % |
-
YOU MAY ALSO LIKE
- Share Market basics for beginners
Share Market jargons in simple terms - Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ? - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - Stock market course tutorial
Stock Market Investment Course explained in simple words. - High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
CONSOLIDATED QUARTERLY RESULT FOR NOVARTIS INDIA LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 1209.2 | 1015.2 | 801.7 | 761.3 | 906 | 787.6 | 845.4 | 811.7 | 922.9 | 871 |
| Total Income | 1474.4 | 1083.8 | 885.3 | 925 | 1030.7 | 956.4 | 1065 | 915.9 | 1027 | 974.2 |
| Total Expenditure | 891.2 | 852 | 725.3 | 668.1 | 732.8 | 618.5 | 647.7 | 699.6 | 683.2 | 691.4 |
| Other Income | 265.2 | 68.6 | 83.6 | 163.7 | 124.7 | 168.8 | 219.6 | 104.2 | 104.1 | 103.2 |
| Operating Profit | 583.2 | 231.8 | 160 | 256.9 | 297.9 | 337.9 | 417.3 | 216.3 | 343.8 | 282.8 |
| Interest | 5 | 4.9 | 4.6 | 3 | 4.6 | 7.1 | 1.6 | 1.6 | 1.5 | 1.4 |
| PBDT | 578.2 | 226.9 | 155.4 | 253.9 | 293.3 | 330.8 | 415.7 | 214.7 | 342.3 | 281.4 |
| Depreciation | 13 | 13.8 | 13 | 20.8 | 15.6 | 6.5 | 2.6 | 1.4 | 5.5 | 5.8 |
| Profit Before Tax | 565.2 | 213.1 | 142.4 | 233.1 | 277.7 | 324.3 | 413.1 | 213.3 | 336.8 | 275.6 |
| Tax | 41.4 | 29.6 | 66.3 | -17.1 | 75.1 | 87.5 | 147.4 | 66.5 | 79.4 | 71.5 |
| Profit After Tax | 523.8 | 183.5 | 76.1 | 250.2 | 202.6 | 236.8 | 265.7 | 146.8 | 257.4 | 204.1 |
| Net Profit | 523.8 | 183.5 | 76.1 | 250.2 | 202.6 | 236.8 | 265.7 | 146.8 | 257.4 | 204.1 |
| Equity Capital | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 |
| Face Value (IN RS) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Calculated EPS | 21.22 | 7.44 | 3.08 | 10.14 | 8.21 | 9.59 | 10.77 | 5.95 | 10.43 | 8.27 |
| Diluted Eps After Extraordinary Items | 21.21 | 7.43 | 3.08 | 10.13 | 8.21 | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 |
| Diluted Eps Before Extraordinary Items | 21.21 | 7.43 | 3.08 | 10.13 | 8.21 | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 |
STANDALONE QUARTERLY RESULT FOR NOVARTIS INDIA LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 1209.2 | 1015.2 | 801.7 | 761.3 | 906 | 787.6 | 845.4 | 811.7 | 922.9 | 871 |
| Total Income | 1474.4 | 1083.8 | 885.3 | 925 | 1030.7 | 956.4 | 1065 | 915.9 | 1027 | 974.2 |
| Total Expenditure | 891.2 | 852 | 725.3 | 668.1 | 732.8 | 618.5 | 647.7 | 699.6 | 683.2 | 691.4 |
| Other Income | 265.2 | 68.6 | 83.6 | 163.7 | 124.7 | 168.8 | 219.6 | 104.2 | 104.1 | 103.2 |
| Operating Profit | 583.2 | 231.8 | 160 | 256.9 | 297.9 | 337.9 | 417.3 | 216.3 | 343.8 | 282.8 |
| Interest | 5 | 4.9 | 4.6 | 3 | 4.6 | 7.1 | 1.6 | 1.6 | 1.5 | 1.4 |
| PBDT | 578.2 | 226.9 | 155.4 | 253.9 | 293.3 | 330.8 | 415.7 | 214.7 | 342.3 | 281.4 |
| Depreciation | 13 | 13.8 | 13 | 20.8 | 15.6 | 6.5 | 2.6 | 1.4 | 5.5 | 5.8 |
| Profit Before Tax | 565.2 | 213.1 | 142.4 | 233.1 | 277.7 | 324.3 | 413.1 | 213.3 | 336.8 | 275.6 |
| Tax | 41.4 | 29.6 | 66.3 | -17.1 | 75.1 | 87.5 | 147.4 | 66.5 | 79.4 | 71.5 |
| Profit After Tax | 523.8 | 183.5 | 76.1 | 250.2 | 202.6 | 236.8 | 265.7 | 146.8 | 257.4 | 204.1 |
| Net Profit | 523.8 | 183.5 | 76.1 | 250.2 | 202.6 | 236.8 | 265.7 | 146.8 | 257.4 | 204.1 |
| Equity Capital | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 | 123.4 |
| Face Value (IN RS) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Calculated EPS | 21.22 | 7.44 | 3.08 | 10.14 | 8.21 | 9.59 | 10.77 | 5.95 | 10.43 | 8.27 |
| Diluted Eps After Extraordinary Items | 21.21 | 7.43 | 3.08 | 10.13 | 8.21 | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 |
| Diluted Eps Before Extraordinary Items | 21.21 | 7.43 | 3.08 | 10.13 | 8.21 | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 |
CONSOLIDATED ANNUAL RESULT FOR NOVARTIS INDIA LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 3998.7 | 3787.4 | 3350.7 |
| Total Income | 4330.6 | 4368.5 | 3967.5 |
| Total Expenditure | 3727.6 | 3136.6 | 2698.1 |
| Other Income | 331.9 | 581.1 | 616.8 |
| Operating Profit | 603 | 1231.9 | 1269.4 |
| Interest | 48.3 | 17.5 | 14.9 |
| Exceptional Items | -496.4 | ||
| PBDT | 58.3 | 1214.4 | 1254.5 |
| Depreciation | 96.5 | 60.6 | 26.1 |
| Profit Before Tax | -38.2 | 1153.8 | 1228.4 |
| Tax | -1 | 120.2 | 376.5 |
| Profit After Tax | -37.2 | 1033.6 | 851.9 |
| Net Profit | -37.2 | 1033.6 | 851.9 |
| Equity Capital | 123.4 | 123.4 | 123.4 |
| Face Value (IN RS) | 5 | 5 | 5 |
| Reserves | 6793.6 | 7633.2 | 7324.8 |
| Calculated EPS | -1.51 | 41.88 | 34.52 |
| Diluted Eps After Extraordinary Items | -1.51 | 41.86 | 34.5 |
| Diluted Eps Before Extraordinary Items | -1.51 | 41.86 | 34.5 |
STANDALONE ANNUAL RESULT FOR NOVARTIS INDIA LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 3998.7 | 3787.4 | 3350.7 |
| Total Income | 4330.6 | 4368.5 | 3967.5 |
| Total Expenditure | 3727.6 | 3136.6 | 2698.1 |
| Other Income | 331.9 | 581.1 | 616.8 |
| Operating Profit | 603 | 1231.9 | 1269.4 |
| Interest | 48.3 | 17.5 | 14.9 |
| Exceptional Items | -496.4 | ||
| PBDT | 58.3 | 1214.4 | 1254.5 |
| Depreciation | 96.5 | 60.6 | 26.1 |
| Profit Before Tax | -38.2 | 1153.8 | 1228.4 |
| Tax | -1 | 120.2 | 376.5 |
| Profit After Tax | -37.2 | 1033.6 | 851.9 |
| Net Profit | -37.2 | 1033.6 | 851.9 |
| Equity Capital | 123.4 | 123.4 | 123.4 |
| Face Value (IN RS) | 5 | 5 | 5 |
| Reserves | 6793.6 | 7633.2 | 7324.8 |
| Calculated EPS | -1.51 | 41.88 | 34.52 |
| Diluted Eps After Extraordinary Items | -1.51 | 41.86 | 34.5 |
| Diluted Eps Before Extraordinary Items | -1.51 | 41.86 | 34.5 |
CONSOLIDATED PROFIT / LOSS FOR NOVARTIS INDIA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 453.73 Cr | 486.66 Cr | 459.86 Cr | 366.84 Cr |
| Sales | 428.84 Cr | 462.17 Cr | 448.35 Cr | 365.15 Cr |
| Processing Charges / Service Income | 9.15 Cr | 12.19 Cr | 1.88 Cr | 66 Lk |
| Net Sales | 381.35 Cr | 399.87 Cr | 378.74 Cr | 335.07 Cr |
| Increase/Decrease in Stock | 10.74 Cr | -9.12 Cr | 2.35 Cr | 9.86 Cr |
| Raw Material Consumed | 135.88 Cr | 187.26 Cr | 199.34 Cr | 189.98 Cr |
| Other Direct Purchases / Brought in cost | 135.88 Cr | 187.26 Cr | 199.34 Cr | 189.98 Cr |
| Power & Fuel Cost | 53 Lk | 53 Lk | 35 Lk | 18 Lk |
| Electricity & Power | 53 Lk | 53 Lk | 35 Lk | 18 Lk |
| Employee Cost | 108.51 Cr | 101.89 Cr | 35.64 Cr | 22.96 Cr |
| Salaries, Wages & Bonus | 88.73 Cr | 85.05 Cr | 33.14 Cr | 21.04 Cr |
| Contributions to EPF & Pension Funds | 9.05 Cr | 9.22 Cr | 26 Lk | 54 Lk |
| Workmen and Staff Welfare Expenses | 5.33 Cr | 2.47 Cr | 1.85 Cr | 1.13 Cr |
| Other Manufacturing Expenses | 36.52 Cr | 34.49 Cr | 15.51 Cr | 7.54 Cr |
| Sub-contracted / Out sourced services | 33.39 Cr | 31.12 Cr | 12.58 Cr | 4.87 Cr |
| Repairs and Maintenance | 12 Lk | 3 Lk | 0 | 13 Lk |
| General and Administration Expenses | 12.95 Cr | 18.61 Cr | 19.1 Cr | 15.37 Cr |
| Rent , Rates & Taxes | 4.5 Cr | 5.13 Cr | 10.49 Cr | 6.28 Cr |
| Insurance | 42 Lk | 65 Lk | 49 Lk | 44 Lk |
| Printing and stationery | 95 Lk | 1.17 Cr | 26 Lk | 14 Lk |
| Professional and legal fees | 3.99 Cr | 5.05 Cr | 5.06 Cr | 5.42 Cr |
| Traveling and conveyance | 1.63 Cr | 5.1 Cr | 1.78 Cr | 1.88 Cr |
| Selling and Distribution Expenses | 39.77 Cr | 35.66 Cr | 27.98 Cr | 15.87 Cr |
| Advertisement & Sales Promotion | 9.8 Cr | 7.46 Cr | 6.1 Cr | 1.94 Cr |
| Freight and Forwarding | 29.97 Cr | 28.2 Cr | 21.88 Cr | 13.93 Cr |
| Miscellaneous Expenses | 9.77 Cr | 5.04 Cr | 13.39 Cr | 8.05 Cr |
| Bad debts /advances written off | 11 Lk | 1.6 Cr | 0 | 0 |
| Provision for doubtful debts | 10 Lk | 19 Lk | 37 Lk | 17 Lk |
| Loss on disposal of fixed assets(net) | 0 | 14 Lk | 0 | 0 |
| Loss on foreign exchange fluctuations | 14 Lk | 0 | 1.06 Cr | 27 Lk |
| Total Expenditure | 354.67 Cr | 374.36 Cr | 313.66 Cr | 269.81 Cr |
| Other Income | 33.2 Cr | 34.79 Cr | 58.11 Cr | 61.68 Cr |
| Interest Received | 24.17 Cr | 20.96 Cr | 54.36 Cr | 55.19 Cr |
| Profit on sale of Fixed Assets | 4.55 Cr | 0 | 24 Lk | 3.21 Cr |
| Provision Written Back | 1.94 Cr | 17 Lk | 64 Lk | 45 Lk |
| Foreign Exchange Gains | 0 | 14 Lk | 0 | 0 |
| Operating Profit | 59.88 Cr | 60.3 Cr | 123.19 Cr | 126.94 Cr |
| Interest | 7.68 Cr | 4.83 Cr | 1.75 Cr | 1.49 Cr |
| Intereston Fixed deposits | 8 Lk | 4 Lk | 5 Lk | 1 Lk |
| PBDT | 52.2 Cr | 55.47 Cr | 121.44 Cr | 125.45 Cr |
| Depreciation | 12.16 Cr | 9.65 Cr | 6.06 Cr | 2.61 Cr |
| Profit Before Taxation & Exceptional Items | 40.04 Cr | 45.82 Cr | 115.38 Cr | 122.84 Cr |
| Exceptional Income / Expenses | 0 | -49.64 Cr | 0 | 0 |
| Profit Before Tax | 40.04 Cr | -3.82 Cr | 115.38 Cr | 122.84 Cr |
| Provision for Tax | 19.14 Cr | -10 Lk | 12.02 Cr | 37.65 Cr |
| Current Income Tax | 17.89 Cr | 0 | 21.08 Cr | 31.47 Cr |
| Deferred Tax | -3.48 Cr | 34 Lk | 10.34 Cr | 2 Lk |
| Profit After Tax | 20.9 Cr | -3.72 Cr | 103.36 Cr | 85.19 Cr |
| Consolidated Net Profit | 20.9 Cr | -3.72 Cr | 103.36 Cr | 85.19 Cr |
| Profit Balance B/F | 708.04 Cr | 698.16 Cr | 677.94 Cr | 759.72 Cr |
| Appropriations | 728.94 Cr | 694.44 Cr | 781.3 Cr | 844.91 Cr |
| Other Appropriation | 30.78 Cr | 16.5 Cr | 21.58 Cr | 116.07 Cr |
| Equity Dividend % | 200 | 200 | 950 | 500 |
| Earnings Per Share | 8.47 | -1.51 | 41.88 | 34.52 |
| Adjusted EPS | 8.47 | -1.51 | 41.88 | 34.52 |
STANDALONE PROFIT / LOSS FOR NOVARTIS INDIA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 453.73 Cr | 486.66 Cr | 459.86 Cr | 366.84 Cr |
| Sales | 428.84 Cr | 462.17 Cr | 448.35 Cr | 365.15 Cr |
| Processing Charges / Service Income | 9.15 Cr | 12.19 Cr | 1.88 Cr | 66 Lk |
| Net Sales | 381.35 Cr | 399.87 Cr | 378.74 Cr | 335.07 Cr |
| Increase/Decrease in Stock | 10.74 Cr | -9.12 Cr | 2.35 Cr | 9.86 Cr |
| Raw Material Consumed | 135.88 Cr | 187.26 Cr | 199.34 Cr | 189.98 Cr |
| Other Direct Purchases / Brought in cost | 135.88 Cr | 187.26 Cr | 199.34 Cr | 189.98 Cr |
| Power & Fuel Cost | 53 Lk | 53 Lk | 35 Lk | 18 Lk |
| Electricity & Power | 53 Lk | 53 Lk | 35 Lk | 18 Lk |
| Employee Cost | 108.51 Cr | 101.89 Cr | 35.64 Cr | 22.96 Cr |
| Salaries, Wages & Bonus | 88.73 Cr | 85.05 Cr | 33.14 Cr | 21.04 Cr |
| Contributions to EPF & Pension Funds | 9.05 Cr | 9.22 Cr | 26 Lk | 54 Lk |
| Workmen and Staff Welfare Expenses | 5.33 Cr | 2.47 Cr | 1.85 Cr | 1.13 Cr |
| Other Manufacturing Expenses | 36.52 Cr | 34.49 Cr | 15.51 Cr | 7.54 Cr |
| Sub-contracted / Out sourced services | 33.39 Cr | 31.12 Cr | 12.58 Cr | 4.87 Cr |
| Repairs and Maintenance | 12 Lk | 3 Lk | 0 | 13 Lk |
| General and Administration Expenses | 12.95 Cr | 18.61 Cr | 19.1 Cr | 15.37 Cr |
| Rent , Rates & Taxes | 4.5 Cr | 5.13 Cr | 10.49 Cr | 6.28 Cr |
| Insurance | 42 Lk | 65 Lk | 49 Lk | 44 Lk |
| Printing and stationery | 95 Lk | 1.17 Cr | 26 Lk | 14 Lk |
| Professional and legal fees | 3.99 Cr | 5.05 Cr | 5.06 Cr | 5.42 Cr |
| Traveling and conveyance | 1.63 Cr | 5.1 Cr | 1.78 Cr | 1.88 Cr |
| Selling and Distribution Expenses | 39.77 Cr | 35.66 Cr | 27.98 Cr | 15.87 Cr |
| Advertisement & Sales Promotion | 9.8 Cr | 7.46 Cr | 6.1 Cr | 1.94 Cr |
| Freight and Forwarding | 29.97 Cr | 28.2 Cr | 21.88 Cr | 13.93 Cr |
| Miscellaneous Expenses | 9.77 Cr | 5.04 Cr | 13.39 Cr | 8.05 Cr |
| Bad debts /advances written off | 11 Lk | 1.6 Cr | 0 | 0 |
| Provision for doubtful debts | 10 Lk | 19 Lk | 37 Lk | 17 Lk |
| Loss on disposal of fixed assets(net) | 0 | 14 Lk | 0 | 0 |
| Loss on foreign exchange fluctuations | 14 Lk | 0 | 1.06 Cr | 27 Lk |
| Total Expenditure | 354.67 Cr | 374.36 Cr | 313.66 Cr | 269.81 Cr |
| Other Income | 33.2 Cr | 34.79 Cr | 58.11 Cr | 61.68 Cr |
| Interest Received | 24.17 Cr | 20.96 Cr | 54.36 Cr | 55.19 Cr |
| Profit on sale of Fixed Assets | 4.55 Cr | 0 | 24 Lk | 3.21 Cr |
| Provision Written Back | 1.94 Cr | 17 Lk | 64 Lk | 45 Lk |
| Foreign Exchange Gains | 0 | 14 Lk | 0 | 0 |
| Operating Profit | 59.88 Cr | 60.3 Cr | 123.19 Cr | 126.94 Cr |
| Interest | 7.68 Cr | 4.83 Cr | 1.75 Cr | 1.49 Cr |
| Intereston Fixed deposits | 8 Lk | 4 Lk | 5 Lk | 1 Lk |
| PBDT | 52.2 Cr | 55.47 Cr | 121.44 Cr | 125.45 Cr |
| Depreciation | 12.16 Cr | 9.65 Cr | 6.06 Cr | 2.61 Cr |
| Profit Before Taxation & Exceptional Items | 40.04 Cr | 45.82 Cr | 115.38 Cr | 122.84 Cr |
| Exceptional Income / Expenses | 0 | -49.64 Cr | 0 | 0 |
| Profit Before Tax | 40.04 Cr | -3.82 Cr | 115.38 Cr | 122.84 Cr |
| Provision for Tax | 19.14 Cr | -10 Lk | 12.02 Cr | 37.65 Cr |
| Current Income Tax | 17.89 Cr | 0 | 21.08 Cr | 31.47 Cr |
| Deferred Tax | -3.48 Cr | 34 Lk | 10.34 Cr | 2 Lk |
| Profit After Tax | 20.9 Cr | -3.72 Cr | 103.36 Cr | 85.19 Cr |
| Consolidated Net Profit | 20.9 Cr | -3.72 Cr | 103.36 Cr | 85.19 Cr |
| Profit Balance B/F | 708.04 Cr | 698.16 Cr | 677.94 Cr | 759.72 Cr |
| Appropriations | 728.94 Cr | 694.44 Cr | 781.3 Cr | 844.91 Cr |
| Other Appropriation | 30.78 Cr | 16.5 Cr | 21.58 Cr | 116.07 Cr |
| Equity Dividend % | 200 | 200 | 950 | 500 |
| Earnings Per Share | 8.47 | -1.51 | 41.88 | 34.52 |
| Adjusted EPS | 8.47 | -1.51 | 41.88 | 34.52 |
CONSOLIDATED CASH FLOW FOR NOVARTIS INDIA LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 40.04 Cr | -3.82 Cr | 115.38 Cr | 122.84 Cr |
| Adjustment | -4.98 Cr | -5.64 Cr | -48.92 Cr | -56.75 Cr |
| Changes In working Capital | -69.08 Cr | 66.72 Cr | -24 Cr | 9.04 Cr |
| Cash Flow after changes in Working Capital | -34.02 Cr | 57.26 Cr | 42.46 Cr | 75.13 Cr |
| Cash Flow from Operating Activities | -69.21 Cr | 38.67 Cr | 44.8 Cr | 113.4 Cr |
| Cash Flow from Investing Activities | 95.16 Cr | 87.04 Cr | -153.25 Cr | 33.13 Cr |
| Cash Flow from Financing Activitie | -36.8 Cr | -35.63 Cr | -30.48 Cr | -120.99 Cr |
| Net Cash Inflow / Outflow | -10.85 Cr | 90.08 Cr | -138.93 Cr | 25.54 Cr |
| Opening Cash & Cash Equivalents | 79.12 Cr | 68.27 Cr | 158.35 Cr | 19.42 Cr |
| Closing Cash & Cash Equivalent | 68.27 Cr | 158.35 Cr | 19.42 Cr | 44.96 Cr |
STANDALONE CASH FLOW FOR NOVARTIS INDIA LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 40.04 Cr | -3.82 Cr | 115.38 Cr | 122.84 Cr |
| Adjustment | -4.98 Cr | -5.64 Cr | -48.92 Cr | -56.75 Cr |
| Changes In working Capital | -69.08 Cr | 66.72 Cr | -24 Cr | 9.04 Cr |
| Cash Flow after changes in Working Capital | -34.02 Cr | 57.26 Cr | 42.46 Cr | 75.13 Cr |
| Cash Flow from Operating Activities | -69.21 Cr | 38.67 Cr | 44.8 Cr | 113.4 Cr |
| Cash Flow from Investing Activities | 95.16 Cr | 87.04 Cr | -153.25 Cr | 33.13 Cr |
| Cash Flow from Financing Activitie | -36.8 Cr | -35.63 Cr | -30.48 Cr | -120.99 Cr |
| Net Cash Inflow / Outflow | -10.85 Cr | 90.08 Cr | -138.93 Cr | 25.54 Cr |
| Opening Cash & Cash Equivalents | 79.12 Cr | 68.27 Cr | 158.35 Cr | 19.42 Cr |
| Closing Cash & Cash Equivalent | 68.27 Cr | 158.35 Cr | 19.42 Cr | 44.96 Cr |
CONSOLIDATED BALANCE SHEET FOR NOVARTIS INDIA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 12.34 Cr | 12.34 Cr | 12.34 Cr | 12.34 Cr |
| Equity - Authorised | 32 Cr | 32 Cr | 32 Cr | 32 Cr |
| Equity - Issued | 12.34 Cr | 12.34 Cr | 12.34 Cr | 12.34 Cr |
| Equity Paid Up | 12.34 Cr | 12.34 Cr | 12.34 Cr | 12.34 Cr |
| Face Value | 5 | 5 | 5 | 5 |
| Total Reserves | 701.8 Cr | 681.58 Cr | 763.36 Cr | 732.48 Cr |
| Profit & Loss Account Balance | 698.16 Cr | 677.94 Cr | 759.72 Cr | 728.84 Cr |
| Reserve excluding Revaluation Reserve | 701.8 Cr | 681.58 Cr | 763.36 Cr | 732.48 Cr |
| Shareholder's Funds | 711.19 Cr | 691.7 Cr | 775.66 Cr | 744.82 Cr |
| Deferred Tax Assets / Liabilities | -30.27 Cr | -27.18 Cr | -15.8 Cr | -15.37 Cr |
| Deferred Tax Assets | 30.27 Cr | 27.18 Cr | 15.8 Cr | 23.24 Cr |
| Deferred Tax Liability | 0 | 0 | 0 | 7.87 Cr |
| Other Long Term Liabilities | 51.35 Cr | 19.6 Cr | 25.18 Cr | 5.29 Cr |
| Long Term Provisions | 80.8 Cr | 1007.5 Cr | 998.39 Cr | 726.33 Cr |
| Total Non-Current Liabilities | 101.88 Cr | 999.92 Cr | 1007.77 Cr | 716.25 Cr |
| Trade Payables | 55.2 Cr | 72.2 Cr | 59.67 Cr | 61.59 Cr |
| Sundry Creditors | 55.2 Cr | 72.2 Cr | 59.67 Cr | 61.59 Cr |
| Other Current Liabilities | 69.64 Cr | 45.34 Cr | 38.03 Cr | 33.54 Cr |
| Advances received from customers | 1.5 Cr | 1.36 Cr | 1.87 Cr | 2.31 Cr |
| Short Term Borrowings | 0 | 0 | 0 | 2 Lk |
| Short Term Provisions | 232.42 Cr | 216.93 Cr | 170.56 Cr | 304.68 Cr |
| Provision for Tax | 210.49 Cr | 130.41 Cr | 128.65 Cr | 265.93 Cr |
| Provision for post retirement benefits | 4.68 Cr | 9.83 Cr | 82 Lk | 16.74 Cr |
| Total Current Liabilities | 357.26 Cr | 334.47 Cr | 268.26 Cr | 399.83 Cr |
| Total Liabilities | 1170.33 Cr | 2026.09 Cr | 2051.69 Cr | 1860.9 Cr |
| Gross Block | 74.81 Cr | 32.94 Cr | 38.92 Cr | 28.36 Cr |
| Less: Accumulated Depreciation | 10.9 Cr | 9.29 Cr | 19.67 Cr | 21.42 Cr |
| Net Block | 63.91 Cr | 23.65 Cr | 19.25 Cr | 6.94 Cr |
| Long Term Loans & Advances | 154.79 Cr | 1148.17 Cr | 1240.75 Cr | 903.63 Cr |
| Other Non Current Assets | 29.28 Cr | 27.49 Cr | 5.59 Cr | 8.44 Cr |
| Total Non-Current Assets | 247.98 Cr | 1199.31 Cr | 1265.59 Cr | 919.01 Cr |
| Inventories | 47.95 Cr | 57.07 Cr | 54.72 Cr | 44.86 Cr |
| Sundry Debtors | 38.73 Cr | 44.56 Cr | 36.16 Cr | 41.47 Cr |
| Debtors more than Six months | 0 | 2.76 Cr | 2.39 Cr | 2.76 Cr |
| Debtors Others | 43.01 Cr | 44.45 Cr | 36.1 Cr | 41.21 Cr |
| Cash and Bank | 498.88 Cr | 517.63 Cr | 555.94 Cr | 596.08 Cr |
| Balances at Bank | 498.88 Cr | 517.63 Cr | 555.94 Cr | 596.08 Cr |
| Other Current Assets | 49.01 Cr | 14.39 Cr | 15.95 Cr | 2.04 Cr |
| Interest accrued and or due on loans | 0 | 0 | 7.62 Cr | 0 |
| Prepaid Expenses | 2.49 Cr | 3.85 Cr | 2.95 Cr | 1.89 Cr |
| Short Term Loans and Advances | 287.78 Cr | 193.13 Cr | 123.29 Cr | 257.44 Cr |
| Advances recoverable in cash or in kind | 15.73 Cr | 1.46 Cr | 1.38 Cr | 1.05 Cr |
| Advance income tax and TDS | 198.31 Cr | 120.06 Cr | 108.77 Cr | 242.63 Cr |
| Total Current Assets | 922.35 Cr | 826.78 Cr | 786.06 Cr | 941.89 Cr |
| Net Current Assets (Including Current Investments) | 565.09 Cr | 492.31 Cr | 517.8 Cr | 542.06 Cr |
| Total Assets | 1170.33 Cr | 2026.09 Cr | 2051.69 Cr | 1860.9 Cr |
| Contingent Liabilities | 426.07 Cr | 422.34 Cr | 419.25 Cr | 398.38 Cr |
| Total Debt | 0 | 0 | 0 | 2 Lk |
| Book Value | 289.36 | 0 | 314.3 | 0 |
| Adjusted Book Value | 289.36 | 281.17 | 314.3 | 301.79 |
STANDALONE BALANCE SHEET FOR NOVARTIS INDIA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 12.34 Cr | 12.34 Cr | 12.34 Cr | 12.34 Cr |
| Equity - Authorised | 32 Cr | 32 Cr | 32 Cr | 32 Cr |
| Equity - Issued | 12.34 Cr | 12.34 Cr | 12.34 Cr | 12.34 Cr |
| Equity Paid Up | 12.34 Cr | 12.34 Cr | 12.34 Cr | 12.34 Cr |
| Face Value | 5 | 5 | 5 | 5 |
| Total Reserves | 701.8 Cr | 681.58 Cr | 763.36 Cr | 732.48 Cr |
| Profit & Loss Account Balance | 698.16 Cr | 677.94 Cr | 759.72 Cr | 728.84 Cr |
| Reserve excluding Revaluation Reserve | 701.8 Cr | 681.58 Cr | 763.36 Cr | 732.48 Cr |
| Shareholder's Funds | 711.19 Cr | 691.7 Cr | 775.66 Cr | 744.82 Cr |
| Deferred Tax Assets / Liabilities | -30.27 Cr | -27.18 Cr | -15.8 Cr | -15.37 Cr |
| Deferred Tax Assets | 30.27 Cr | 27.18 Cr | 15.8 Cr | 23.24 Cr |
| Deferred Tax Liability | 0 | 0 | 0 | 7.87 Cr |
| Other Long Term Liabilities | 51.35 Cr | 19.6 Cr | 25.18 Cr | 5.29 Cr |
| Long Term Provisions | 80.8 Cr | 1007.5 Cr | 998.39 Cr | 726.33 Cr |
| Total Non-Current Liabilities | 101.88 Cr | 999.92 Cr | 1007.77 Cr | 716.25 Cr |
| Trade Payables | 55.2 Cr | 72.2 Cr | 59.67 Cr | 61.59 Cr |
| Sundry Creditors | 55.2 Cr | 72.2 Cr | 59.67 Cr | 61.59 Cr |
| Other Current Liabilities | 69.64 Cr | 45.34 Cr | 38.03 Cr | 33.54 Cr |
| Advances received from customers | 1.5 Cr | 1.36 Cr | 1.87 Cr | 2.31 Cr |
| Short Term Borrowings | 0 | 0 | 0 | 2 Lk |
| Short Term Provisions | 232.42 Cr | 216.93 Cr | 170.56 Cr | 304.68 Cr |
| Provision for Tax | 210.49 Cr | 130.41 Cr | 128.65 Cr | 265.93 Cr |
| Provision for post retirement benefits | 4.68 Cr | 9.83 Cr | 82 Lk | 16.74 Cr |
| Total Current Liabilities | 357.26 Cr | 334.47 Cr | 268.26 Cr | 399.83 Cr |
| Total Liabilities | 1170.33 Cr | 2026.09 Cr | 2051.69 Cr | 1860.9 Cr |
| Gross Block | 74.81 Cr | 32.94 Cr | 38.92 Cr | 28.36 Cr |
| Less: Accumulated Depreciation | 10.9 Cr | 9.29 Cr | 19.67 Cr | 21.42 Cr |
| Net Block | 63.91 Cr | 23.65 Cr | 19.25 Cr | 6.94 Cr |
| Long Term Loans & Advances | 154.79 Cr | 1148.17 Cr | 1240.75 Cr | 903.63 Cr |
| Other Non Current Assets | 29.28 Cr | 27.49 Cr | 5.59 Cr | 8.44 Cr |
| Total Non-Current Assets | 247.98 Cr | 1199.31 Cr | 1265.59 Cr | 919.01 Cr |
| Inventories | 47.95 Cr | 57.07 Cr | 54.72 Cr | 44.86 Cr |
| Sundry Debtors | 38.73 Cr | 44.56 Cr | 36.16 Cr | 41.47 Cr |
| Debtors more than Six months | 0 | 2.76 Cr | 2.39 Cr | 2.76 Cr |
| Debtors Others | 43.01 Cr | 44.45 Cr | 36.1 Cr | 41.21 Cr |
| Cash and Bank | 498.88 Cr | 517.63 Cr | 555.94 Cr | 596.08 Cr |
| Balances at Bank | 498.88 Cr | 517.63 Cr | 555.94 Cr | 596.08 Cr |
| Other Current Assets | 49.01 Cr | 14.39 Cr | 15.95 Cr | 2.04 Cr |
| Interest accrued and or due on loans | 0 | 0 | 7.62 Cr | 0 |
| Prepaid Expenses | 2.49 Cr | 3.85 Cr | 2.95 Cr | 1.89 Cr |
| Short Term Loans and Advances | 287.78 Cr | 193.13 Cr | 123.29 Cr | 257.44 Cr |
| Advances recoverable in cash or in kind | 15.73 Cr | 1.46 Cr | 1.38 Cr | 1.05 Cr |
| Advance income tax and TDS | 198.31 Cr | 120.06 Cr | 108.77 Cr | 242.63 Cr |
| Total Current Assets | 922.35 Cr | 826.78 Cr | 786.06 Cr | 941.89 Cr |
| Net Current Assets (Including Current Investments) | 565.09 Cr | 492.31 Cr | 517.8 Cr | 542.06 Cr |
| Total Assets | 1170.33 Cr | 2026.09 Cr | 2051.69 Cr | 1860.9 Cr |
| Contingent Liabilities | 426.07 Cr | 422.34 Cr | 419.25 Cr | 398.38 Cr |
| Total Debt | 0 | 0 | 0 | 2 Lk |
| Book Value | 289.36 | 0 | 314.3 | 0 |
| Adjusted Book Value | 289.36 | 281.17 | 314.3 | 301.79 |
FINANCIAL RATIOS (CONSOLIDATED) FOR NOVARTIS INDIA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 8.47 | -1.51 | 41.88 | 34.52 |
| CEPS(Rs) | 13.4 | 2.4 | 44.34 | 35.58 |
| DPS(Rs) | 10 | 10 | 47.5 | 25 |
| Book NAV/Share(Rs) | 289.36 | 281.17 | 314.3 | 301.79 |
| Tax Rate(%) | 47.8 | 2.62 | 10.42 | 30.65 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 5.88 | 5.24 | 14.15 | 17.79 |
| EBIT Margin(%) | 10.52 | 0.21 | 25.47 | 33.89 |
| Pre Tax Margin(%) | 8.82 | -0.78 | 25.09 | 33.49 |
| PAT Margin (%) | 4.61 | -0.76 | 22.48 | 23.22 |
| Cash Profit Margin (%) | 7.29 | 1.22 | 23.79 | 23.93 |
| Performance Ratios | ||||
| ROA(%) | 1.74 | -0.18 | 5.09 | 4.35 |
| ROE(%) | 2.91 | -0.53 | 14.07 | 11.21 |
| ROCE(%) | 6.67 | 0.14 | 15.96 | 16.35 |
| Asset Turnover(x) | 0.38 | 0.23 | 0.23 | 0.19 |
| Sales/Fixed Asset(x) | 5.68 | 9.03 | 11.55 | 10.9 |
| Working Capital/Sales(x) | 0.8 | 0.99 | 0.89 | 0.68 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.18 | 0.11 | 0.09 | 0.09 |
| Receivable days | 30.7 | 31.23 | 32.03 | 38.62 |
| Inventory Days | 42.89 | 39.38 | 44.37 | 49.54 |
| Payable days | 69.79 | 130.52 | 119.32 | 110.74 |
| Valuation Parameters | ||||
| PER(x) | 65.18 | 0 | 13.5 | 29.8 |
| PCE(x) | 41.21 | 245.74 | 12.75 | 28.91 |
| Price/Book(x) | 1.91 | 2.1 | 1.8 | 3.41 |
| Yield(%) | 1.81 | 1.69 | 8.4 | 2.43 |
| EV/Net Sales(x) | 2.26 | 2.35 | 2.22 | 5.8 |
| EV/Core EBITDA(x) | 14.42 | 15.58 | 6.81 | 15.3 |
| EV/EBIT(x) | 18.09 | 930.3 | 7.16 | 15.62 |
| EV/CE(x) | 0.74 | 0.46 | 0.41 | 2.61 |
| M Cap / Sales | 3.57 | 3.64 | 3.68 | 7.58 |
| Growth Ratio | ||||
| Net Sales Growth(%) | -12.98 | 4.86 | -5.28 | -11.53 |
| Core EBITDA Growth(%) | 24.31 | 0.7 | 104.3 | 3.04 |
| EBIT Growth(%) | 36.23 | -97.88 | 0 | 6.15 |
| PAT Growth(%) | 107.34 | -117.8 | 2878.49 | -17.58 |
| EPS Growth(%) | 107.34 | -117.8 | 2878.48 | -17.58 |
| Financial Stability Ratios | ||||
| Current Ratio(x) | 2.58 | 2.47 | 2.93 | 2.36 |
| Quick Ratio(x) | 2.45 | 2.3 | 2.73 | 2.24 |
| Interest Cover(x) | 6.21 | 0.21 | 66.93 | 83.44 |
FINANCIAL RATIOS (STANDALONE) FOR NOVARTIS INDIA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 8.47 | -1.51 | 41.88 | 34.52 |
| CEPS(Rs) | 13.4 | 2.4 | 44.34 | 35.58 |
| DPS(Rs) | 10 | 10 | 47.5 | 25 |
| Book NAV/Share(Rs) | 289.36 | 281.17 | 314.3 | 301.79 |
| Tax Rate(%) | 47.8 | 2.62 | 10.42 | 30.65 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 5.88 | 5.24 | 14.15 | 17.79 |
| EBIT Margin(%) | 10.52 | 0.21 | 25.47 | 33.89 |
| Pre Tax Margin(%) | 8.82 | -0.78 | 25.09 | 33.49 |
| PAT Margin (%) | 4.61 | -0.76 | 22.48 | 23.22 |
| Cash Profit Margin (%) | 7.29 | 1.22 | 23.79 | 23.93 |
| Performance Ratios | ||||
| ROA(%) | 1.74 | -0.18 | 5.09 | 4.35 |
| ROE(%) | 2.91 | -0.53 | 14.07 | 11.21 |
| ROCE(%) | 6.67 | 0.14 | 15.96 | 16.35 |
| Asset Turnover(x) | 0.38 | 0.23 | 0.23 | 0.19 |
| Sales/Fixed Asset(x) | 5.68 | 9.03 | 11.55 | 10.9 |
| Working Capital/Sales(x) | 0.8 | 0.99 | 0.89 | 0.68 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.18 | 0.11 | 0.09 | 0.09 |
| Receivable days | 30.7 | 31.23 | 32.03 | 38.62 |
| Inventory Days | 42.89 | 39.38 | 44.37 | 49.54 |
| Payable days | 69.79 | 130.52 | 119.32 | 110.74 |
| Valuation Parameters | ||||
| PER(x) | 65.18 | 0 | 13.5 | 29.8 |
| PCE(x) | 41.21 | 245.74 | 12.75 | 28.91 |
| Price/Book(x) | 1.91 | 2.1 | 1.8 | 3.41 |
| Yield(%) | 1.81 | 1.69 | 8.4 | 2.43 |
| EV/Net Sales(x) | 2.26 | 2.35 | 2.22 | 5.8 |
| EV/Core EBITDA(x) | 14.42 | 15.58 | 6.81 | 15.3 |
| EV/EBIT(x) | 18.09 | 930.3 | 7.16 | 15.62 |
| EV/CE(x) | 0.74 | 0.46 | 0.41 | 2.61 |
| M Cap / Sales | 3.57 | 3.64 | 3.68 | 7.58 |
| Growth Ratio | ||||
| Net Sales Growth(%) | -12.98 | 4.86 | -5.28 | -11.53 |
| Core EBITDA Growth(%) | 24.31 | 0.7 | 104.3 | 3.04 |
| EBIT Growth(%) | 36.23 | -97.88 | 0 | 6.15 |
| PAT Growth(%) | 107.34 | -117.8 | 2878.49 | -17.58 |
| EPS Growth(%) | 107.34 | -117.8 | 2878.48 | -17.58 |
| Financial Stability Ratios | ||||
| Current Ratio(x) | 2.58 | 2.47 | 2.93 | 2.36 |
| Quick Ratio(x) | 2.45 | 2.3 | 2.73 | 2.24 |
| Interest Cover(x) | 6.21 | 0.21 | 66.93 | 83.44 |
SHARE HOLDING PATTERN FOR NOVARTIS INDIA LIMITED
| Date | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| FII % | 0.14 | 0.17 | 0.17 | 0.17 | 0.23 | 0.32 | 0.19 | 0.19 | 0.19 | 0.19 |
| DII % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public % | 28.41 | 28.38 | 28.38 | 28.38 | 28.33 | 28.48 | 28.61 | 28.61 | 28.61 | 28.61 |
PEER COMPARISON FOR NOVARTIS INDIA LIMITED
CORPORATE ACTIONS FOR NOVARTIS INDIA
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 27-Sep-2024 | Board Meeting - Quarterly Results | 25-Oct-2024 |
| BSE 10-May-2024 | Book Closure - Rs.25.0000 per share(500%)Final Dividend & A.G.M. | 24-Jul-2024 31-Jul-2024 |
| BSE 10-May-2024 | Dividend - Rs.25.0000 per share(500%)Final Dividend | |
| BSE 27-Mar-2024 | Board Meeting - Final Dividend & Audited Results | 10-May-2024 |
| BSE 27-Dec-2023 | Board Meeting - Quarterly Results | 25-Jan-2024 |
| BSE 03-Oct-2023 | Board Meeting - Quarterly Results | 27-Oct-2023 |
| BSE 20-Jul-2023 | Dividend - Rs.37.5000 per share(750%)Special Dividend | |
| BSE 30-Jun-2023 | Board Meeting - Quarterly Results | 26-Jul-2023 |
| BSE 10-May-2023 | Board Meeting - Special Dividend & Final Dividend | 10-May-2023 |
| BSE 10-May-2023 | Book Closure - 27/08/2023 Equity Rs.37.5000 per share(750%)Special Dividend & Rs.10.0000 per share(200%)Final Dividend | 21-Jul-2023 28-Jul-2023 |
| BSE 10-May-2023 | AGM - 27/08/2023 Equity Rs.37.5000 per share(750%)Special Dividend & Rs.10.0000 per share(200%)Final Dividend | 28-Jul-2023 28-Jul-2023 |
| BSE 31-Mar-2023 | Board Meeting - Dividend & Audited Results | 10-May-2023 |
| BSE 27-Dec-2022 | Board Meeting - Quarterly Results | 08-Feb-2023 |
| BSE 30-Sep-2022 | Board Meeting - Quarterly Results | 09-Nov-2022 |
| BSE 30-Jun-2022 | Board Meeting - Quarterly Results | 27-Jul-2022 |
| BSE 19-May-2022 | Book Closure - Rs.10.0000 per share(200%)Final Dividend & A.G.M. | 22-Jul-2022 29-Jul-2022 |
| BSE 19-May-2022 | AGM - Rs.10.0000 per share(200%)Final Dividend & A.G.M. | 29-Jul-2022 29-Jul-2022 |
| BSE 19-May-2022 | Dividend - Rs.10.0000 per share(200%)Final Dividend | |
| BSE 31-Mar-2022 | Board Meeting - Final Dividend & Audited Results | 19-May-2022 |
| BSE 31-Dec-2021 | Board Meeting - Quarterly Results | 10-Feb-2022 |
| BSE 30-Sep-2021 | Board Meeting - Quarterly Results | 11-Nov-2021 |
CORPORATE ANNOUNCEMENTS FOR NOVARTIS INDIA
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 28-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Filing of intimation regarding the publication of financial results for the Quarter and Half year ended September 30 2024 in newspapers i.e Financial express and Navshakti on October 26 2024 |
| BSE 25-Oct-2024 | Outcome FILE | Filing Of The Outcome Of Board Meeting And Unaudited Financial Results For The Quarter And Half Year Ended September 30 2024 Filing of the outcome of Board Meeting and Unaudited Financial Results for the quarter and half year ended September 30 2024 |
| BSE 24-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation for issue of duplicate share certificates received from the Companys RTA dated October 23 2024 |
| BSE 24-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of Intimation for loss of share certificates received from Companys RTA dated October 23 2024 |
| BSE 11-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Filing of Certificate dated 03.10.2024 under regulation 74(5) received from the Companys RTA for the quarter ended Sept 30 2024 |
| BSE 09-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation for re-issue of share certificate received from Companys RTA dated 08.10.2024 |
| BSE 30-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of Intimation u/r 39(3) for the loss of share certificates received from Companys RTA dated September 28 2024 |
| BSE 27-Sep-2024 | Intimation FILE | Board Meeting Intimation for Board Meeting Intimation For The Consideration And Approval Of Unaudited Financial Results For The Quarter Ended September 30 2024. NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve the Unaudited Financial Results for the quarter ended September 30 2024 |
| BSE 27-Sep-2024 | Intimation FILE | Closure of Trading Window Intimation for the closure of Trading Window for the quarter ended September 30 2024. The trading window will be closed from October 01 2024. The trading window will open 48 hours after the said financial results for the quarter are declared to the Stock Exchange. |
| BSE 26-Sep-2024 | General Announcements FILE | Filing Of Clarification On The Email Received From BSE Dated September 26 2024 On The Rumor In Relation To Acquisition Of Novartis India Limited From Its Swiss Parent Company By Alkem Labs Filing of clarification on the email received from BSE dated September 26 2024 on the rumor in relation to acquisition of Novartis India Limited from its Swiss Parent Company by Alkem Labs. |
| BSE 26-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation u/r 39(3) for the loss of share certificate received from Companys RTA dated September 26 2024 |
| BSE 26-Sep-2024 | General - | Clarification sought from Novartis India Ltd The Exchange has sought clarification from Novartis India Ltd on September 26 2024 with reference to news appeared in www.cnbctv18.com dated September 26 2024 quoting "Alkem Labs in talks to acquire Novartis India from its Swiss parent" The reply is awaited. |
| BSE 25-Sep-2024 | General Announcements FILE | Intimation Of Acquiring Of DESFERAL® (Deferoxamine) Globally From Novartis Pharma AG By Mitem Pharma. The Disclosure In This Regard Is Made By Mitem Pharma Through Press Release Over Businesswire On September 25 2024. The Company Novartis India Limited has been importing DESFERAL (deforoxamine) from Novartis Pharma AG and selling it in India. This intimation is filed to inform that DESFERAL (deforoxamine) is acquired by Miten Pharma globally from Novartis Pharma AG. |
| BSE 23-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation u/r 39(3) for loss of share certificate received from Companys RTA dated September 22 2024. |
| BSE 12-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation u/r 39(3) for loss of share certificates received from the Companys RTA dated September 12 2024. |
| BSE 12-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation u/r 39(3) for Issues of Duplicate Share Certificates received from the Companys RTA dated September 11 2024 |
| BSE 09-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation received from RTA for the loss of share certificate u/r 39(3) dated September 07 2024 |
| BSE 02-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of Intimation received from Company`s Registrar and Share Transfer Agent under Regulation 39(3) of the SEBI LODR regulations for the Loss of Share Certificate by the shareholders as on September 01 2024. |
| BSE 30-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation received from RTA for the loss of share certificate u/r 39(3) dated 30th August 2024 |
| BSE 29-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation received from RTA for the loss of share certificate u/r 39(3) dated 29th August 2024 |
| BSE 26-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of Intimation received from RTA for the loss of share certificate u/r. 39(3) dated 24th August 2024. |
| BSE 20-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation for the issue of duplicate share certificate as per the letter received from RTA dated 19.08.2024 |
| BSE 16-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation for loss of Share Certificate as received from RTA dated 15.08.2024 u/r. 39(3) |
| BSE 11-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing of intimation received from RTA for the Loss of share certificate by the Shareholder as of August 09 2024. |
| BSE 05-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Filing the intimation received from Registrar and Share Transfer Agent on the loss of Share Certificate dated August 03 2024. |
| BSE 02-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation under regulation 39(3) of SEBI (LODR) Regulations 2015 regarding loss of share certificates. |
| BSE 01-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Filing of Voting Results and Scrutinizers Report for the 76th Annual General Meeting of Novartis India Limited held on July 31 2024 |
| BSE 01-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Outcome of AGM Outcome of Annual General Meeting held on July 31 2024 of Novartis India Limited |
| BSE 30-Jul-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Intimation of Newspaper Advertisement regarding publication of Unaudited Financial results for First Quarter ended June 30 2024. |
| BSE 29-Jul-2024 | Outcome FILE | Results - Unaudited Financial Results For The First Quarter Ended June 30 2024. Results - Unaudited Financial Results for the first Quarter ended June 30 2024. |
INSIDER TRADING FOR NOVARTIS INDIA
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Insider trading details found | |||
BULK BLOCK DEALS FOR NOVARTIS INDIA LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Bulk Block details found | |||
DIVIDEND BY NOVARTIS INDIA LIMITED
| Ex Dividend Date | Dividend Type | Dividend |
|---|---|---|
| 23-Jul-2024 | DIVIDEND | 25 |
| 20-Jul-2023 | SPECIAL DIVIDEND | 37.5 |
| 20-Jul-2023 | DIVIDEND | 10 |
| 20-Jul-2022 | DIVIDEND | 10 |
| 17-Aug-2021 | DIVIDEND | 10 |
SPLIT / BONUS BY NOVARTIS INDIA LIMITED
No Split / Bonus details found
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
